Fosamax vs Prolia (Denosumab): Side-Effect Profile Head-to-Head

What Are These Two Drugs and How Do They Work?

Alendronate (Fosamax) is an oral bisphosphonate, a class of drug that attaches to bone mineral and slows down the osteoclasts (the cells that break bone down). Denosumab (Prolia) is a monoclonal antibody that blocks RANK Ligand, a protein that drives osteoclast activity. The two drugs both reduce bone resorption, but through completely different biological routes, which is exactly why their side-effect profiles diverge so sharply.

Alendronate has been on the market since 1995 and has decades of real-world data in women. Denosumab was approved by the FDA in 2010 for postmenopausal osteoporosis and has a shorter post-marketing track record, though its trial data are strong.

How Each Drug Reaches Your Bones

Alendronate is absorbed through the GI tract, but only about 0.5 to 1% of an oral dose is actually absorbed into the bloodstream. That low absorption is why the dosing rules are strict: take it first thing in the morning, with a full glass of water, stay upright for 30 minutes, eat nothing for 30 minutes afterward. Break those rules and the drug either doesn't work or burns your esophagus.

Denosumab bypasses the GI tract entirely. A 60 mg subcutaneous injection into the abdomen, thigh, or upper arm every six months delivers drug directly into the bloodstream. Absorption is not a variable. That eliminates GI side effects but introduces a new set of biological consequences.

GI Side Effects: Alendronate's Most Common Problem

The GI burden is where alendronate loses ground for many women. Esophageal irritation, heartburn, acid reflux, and esophageal ulceration are the most frequently reported reasons women stop taking it.

What the Numbers Show

In the FIT (Fracture Intervention Trial), published in JAMA in 1998, upper GI adverse events were reported in approximately 30% of alendronate-treated postmenopausal women over three years. The trial enrolled 2,027 women with low femoral neck bone density. Symptomatic esophageal side effects led to discontinuation in a meaningful subset.

For women with Barrett's esophagus, active esophageal disease, or an inability to sit or stand upright for 30 minutes (a real practical barrier for women with severe arthritis or mobility issues), alendronate is generally avoided.

Why Women May Be More Susceptible

Women report GI side effects from bisphosphonates at higher rates than men in observational studies, though sex-specific pharmacokinetic data are limited and most trials enrolled predominantly female cohorts without sex-stratified GI analyses. This is an evidence gap worth naming plainly: we know the overall GI signal is real, but we do not have well-powered head-to-head data isolating sex as a variable.

Gastrointestinal motility also slows during the luteal phase of the menstrual cycle and after menopause due to lower progesterone and estrogen effects on gut function, which may intensify esophageal exposure to alendronate in some women.

Denosumab Side Effects: The Trade-Off You Need to Know

Denosumab has a cleaner GI profile, but it comes with side effects that are in some ways more serious and less forgiving.

Hypocalcemia (Low Calcium)

Denosumab suppresses bone resorption so effectively that calcium released from bone is reduced. The result can be clinically significant hypocalcemia, especially in women with:

• Vitamin D deficiency (very common in postmenopausal women)
• Kidney disease (reduced vitamin D activation)
• Malabsorption conditions (celiac disease, Crohn's, bariatric surgery history)

The FREEDOM trial, published in the New England Journal of Medicine in 2009, enrolled 7,808 postmenopausal women aged 60 to 90. Hypocalcemia was more common in denosumab-treated women than in the placebo group. Before every denosumab injection, your prescriber should check that your calcium and vitamin D levels are adequate. Supplementing with at least 1,000 mg of calcium and 400 IU of vitamin D daily is part of the standard protocol.

Musculoskeletal Pain

Back pain, joint pain, and muscle pain are reported in 10 to 25% of denosumab recipients. These symptoms are often mild and self-limiting, but they can be significant enough to affect quality of life. Alendronate also causes musculoskeletal pain, sometimes acutely in the first days after a dose (an acute-phase reaction more commonly seen with IV bisphosphonates but occasionally with oral forms).

Infections: A Signal Worth Watching

Denosumab's RANK Ligand blockade has immune-system effects beyond bone. RANK Ligand is expressed on immune cells, and its inhibition may slightly increase susceptibility to certain infections. In the FREEDOM trial, serious infections, including skin infections (cellulitis), were reported at a higher rate in the denosumab group (4.1% vs 3.3% in placebo). This is a modest absolute difference, but it is real and should be discussed if you have recurrent infections or are immunocompromised.

The Rebound Fracture Risk: Denosumab's Biggest Liability

This is the side effect that separates denosumab from alendronate most sharply. When you stop denosumab, bone turnover accelerates rapidly, and bone mineral density can drop below pre-treatment levels within 12 months. Multiple post-marketing reports and observational studies have documented multiple simultaneous vertebral fractures occurring after denosumab discontinuation, a phenomenon not seen with bisphosphonates.

The WomanRx clinical team uses the following decision framework for women approaching denosumab discontinuation:

The Denosumab Transition Framework

1. Never stop denosumab without a transition plan.
2. If stopping is necessary (side effects, cost, preference), transition to an oral or IV bisphosphonate within 3 to 6 months of the last injection to blunt rebound bone loss.
3. Bone turnover markers (serum CTX) should be checked 3 months after the last injection to guide transition timing.
4. Women who are transitioning due to pregnancy (or who become pregnant) need individualized planning given bisphosphonate teratogenicity concerns (see pregnancy section below).

Alendronate does not carry this rebound risk. Its effects persist in bone tissue for months to years after stopping because bisphosphonates bind tightly to hydroxyapatite in bone mineral.

Osteonecrosis of the Jaw and Atypical Femoral Fractures: Rare but Shared

Both drugs carry a small risk of two rare but serious conditions.

Osteonecrosis of the Jaw (ONJ)

ONJ is a rare condition in which bone in the jaw fails to heal, typically after dental procedures. The risk is far higher with IV bisphosphonates used in cancer treatment than with oral alendronate for osteoporosis. With oral alendronate, the estimated incidence is roughly 1 in 10,000 to 1 in 100,000 patient-years. With denosumab for osteoporosis (not cancer-dose regimens), the risk appears similarly low. Before starting either drug, a dental check is standard practice. Invasive dental procedures should ideally be completed before beginning therapy.

Atypical Femoral Fractures (AFFs)

AFFs are stress fractures of the femoral shaft, occurring with minimal trauma, and are associated with long-term suppression of bone turnover. Both bisphosphonates and denosumab have been associated with AFFs. The absolute risk is low: approximately 3.2 to 50 cases per 100,000 person-years depending on duration of use. Pain in the thigh or groin before a fracture occurs is an early warning sign that should be reported immediately.

Fracture Efficacy: Putting the Numbers in Context

The side-effect comparison only makes sense alongside the efficacy data.

| Fracture Type | Alendronate (FIT, 1998) | Denosumab (FREEDOM, 2009) | |---|---|---| | Vertebral | 47% relative risk reduction | 68% relative risk reduction | | Hip | 51% relative risk reduction | 40% relative risk reduction | | Non-vertebral | 16% relative risk reduction | 20% relative risk reduction |

Denosumab shows a larger vertebral fracture reduction. Alendronate shows a numerically larger hip fracture reduction in the FIT trial, though direct comparison across different trials and different populations is not straightforward. No prospective head-to-head trial comparing fracture outcomes of these two drugs in the same population has been published. This is a genuine evidence gap, and extrapolating across trials should be done carefully.

As The Menopause Society's 2023 position statement on osteoporosis notes: "Both bisphosphonates and denosumab are appropriate first-line options for postmenopausal osteoporosis, and selection should be individualized based on patient characteristics, comorbidities, and preference."

Pregnancy, Lactation, and Contraception: What You Must Know

Both alendronate and denosumab are contraindicated in pregnancy. This is not a nuanced clinical gray area.

Alendronate in Pregnancy

Alendronate carries FDA Pregnancy Category C (pre-2015 labeling), reflecting animal data showing fetal harm at high doses, with insufficient human data. Bisphosphonates incorporate into bone mineral and can remain in the skeleton for years. There are case reports of women who conceived while on or shortly after stopping alendronate delivering healthy infants, but the potential for fetal skeletal effects from bone-stored drug cannot be excluded.

Women of reproductive age who are prescribed alendronate for conditions such as glucocorticoid-induced osteoporosis or PCOS-related bone loss should use reliable contraception.

Denosumab in Pregnancy

Denosumab is FDA-classified as contraindicated in pregnancy. Animal studies demonstrate that RANK Ligand inhibition during fetal development causes significant fetal lymph node abnormalities, tooth bud alterations, and impaired bone development. RANK Ligand is biologically active during fetal skeletal and immune development. Denosumab also has a half-life of approximately 25 to 28 days, meaning it clears the bloodstream faster than bisphosphonates, but fetal exposure from a prior injection remains a concern.

Women of reproductive age should use effective contraception during denosumab treatment and for at least 5 months after the last dose, per the FDA label.

Lactation

Neither drug is recommended during breastfeeding. Human lactation data for both alendronate and denosumab are essentially absent. Given that denosumab is a large-molecule antibody and alendronate has poor oral bioavailability in adults, theoretical infant exposure may be low, but "may be low" is not a sufficient basis for recommending use during lactation. Shared decision-making with your prescriber is required.

Premenopausal Women and PCOS

Premenopausal women with conditions causing bone loss (glucocorticoid use, anorexia, PCOS-related low estrogen, premature ovarian insufficiency) represent a group where alendronate has more published data than denosumab. Denosumab is not FDA-approved for premenopausal osteoporosis. The American Society for Reproductive Medicine does not have specific guidance on denosumab in this population, and use in premenopausal women requires specialist input and compelling indication.

Who This Is Right For (and Who It Is Not), by Life Stage

Postmenopausal Women (Most Common Scenario)

Both drugs are appropriate first-line options. Alendronate is often preferred when:

• Cost is a concern (generic alendronate is inexpensive)
• You can reliably follow dosing rules (upright, fasting, weekly)
• You have no significant esophageal disease
• You want a drug you can stop without a complex transition plan

Denosumab is often preferred when:

• You cannot tolerate oral bisphosphonates due to GI disease
• You have chronic kidney disease (alendronate is generally avoided when creatinine clearance falls below 35 mL/min; denosumab can be used with monitoring)
• You have difficulty with weekly oral dosing (cognitive decline, swallowing difficulty)
• Your fracture risk is very high and you want the larger vertebral fracture reduction seen in FREEDOM
• You commit to staying on it or have a clear transition plan

Perimenopausal Women

Bone loss accelerates sharply in the two to three years surrounding the final menstrual period, driven by falling estrogen. For perimenopausal women whose DEXA shows osteoporosis or whose FRAX score indicates high 10-year fracture risk, treatment should not be delayed pending full menopause. Alendronate has data in this transition window; denosumab's label specifies postmenopausal status, which is a practical labeling consideration.

Women with PCOS or Premature Ovarian Insufficiency (POI)

PCOS can be associated with either higher or lower bone density depending on androgen levels, body weight, and menstrual regularity. Women with POI have significantly lower estrogen and face bone loss at a young age. For both groups, the foundational treatment is hormone replacement to restore estrogen levels, not anti-resorptives as a first step. If anti-resorptive therapy is needed despite adequate estrogen replacement, alendronate has more published experience in premenopausal women than denosumab.

Women with Kidney Disease

This is a scenario where denosumab has a real practical edge. Alendronate's prescribing information states it should not be used when creatinine clearance is below 35 mL/min. Denosumab does not require dose adjustment for kidney disease, though hypocalcemia risk increases with worsening renal function and requires careful calcium and vitamin D management.

Dosing, Administration, and Practical Differences

| Feature | Alendronate (Fosamax) | Denosumab (Prolia) | |---|---|---| | Route | Oral tablet | Subcutaneous injection | | Frequency | Once weekly (70 mg) or once daily (10 mg) | Every 6 months | | Fasting required | Yes, 30 minutes minimum | No | | Upright posture required | Yes, 30 minutes post-dose | No | | Renal restriction | Avoid if CrCl <35 mL/min | No dose adjustment required | | Generic available | Yes, widely available | No (brand only as of 2025) | | Cost (approximate monthly) | $10 to $30 generic | $300 to $400+ per injection | | Stopping safely | Can stop without transition plan | Requires transition to bisphosphonate |

Monitoring: What to Expect on Each Drug

On alendronate, bone mineral density (BMD) is typically rechecked by DEXA every 1 to 2 years initially, then every 2 to 3 years once stable. Bone turnover markers (serum CTX, P1NP) can confirm the drug is working and that you are absorbing it adequately.

On denosumab, BMD and bone turnover markers are also tracked. Serum calcium should be checked before each injection. Annual calcium and vitamin D status review is standard. If you miss an injection by more than a few weeks, bone turnover can begin to rebound, making adherence to the every-6-month schedule more critical than with alendronate.

Switching From Fosamax to Prolia (Denosumab): What to Expect

Switching from alendronate to denosumab is straightforward. You stop the oral drug and begin the injection at the point where the next alendronate dose would have been due, or at the next clinical visit.

BMD typically continues to improve after the switch, and some women who had plateau-level BMD on alendronate see further gains on denosumab. A published analysis of FREEDOM Extension data showed continued BMD increases over 10 years in women who remained on denosumab, suggesting long-term efficacy without the tolerance ceiling seen with some bisphosphonates.

The critical message: switching from denosumab back to alendronate requires timing. If denosumab is discontinued without bridging, rebound vertebral fractures are a documented risk. Most guidelines recommend beginning a bisphosphonate within 3 to 6 months of the last denosumab dose.

A Note on the Evidence Gap for Women

Osteoporosis trials have enrolled predominantly women, which is one area where women's health research is relatively stronger than other fields. The FIT trial was 100% female, and FREEDOM enrolled women only. This means the fracture and safety data from these trials apply directly to you without extrapolation from male cohorts. Sex-stratified analyses of GI tolerability, immune effects, and pharmacokinetics across menstrual cycle phases or hormone therapy co-use remain limited. Women taking concurrent menopausal hormone therapy (MHT) represent a growing subgroup; combining estrogen with either anti-resorptive can produce additive BMD gains, but fracture outcome data for the combination are less definitive than for either treatment alone.

"For women who are already on hormone therapy and ask whether they still need a bone-specific drug, the answer depends entirely on their DEXA result and FRAX score at the time of that conversation, not on an assumption that estrogen alone is enough," says Dr. Elena Vasquez, MD, WomanRx Editorial Board Member and NAMS-certified menopause practitioner. "Alendronate and denosumab each have a role even in women on MHT, and that discussion should happen at the menopause visit, not after a fracture."